AustLII Home | Databases | WorldLII | Search | Feedback

Edited Legal Collections Data

You are here:  AustLII >> Databases >> Edited Legal Collections Data >> 2019 >> [2019] ELECD 1285

Database Search | Name Search | Recent Articles | Noteup | LawCite | Help

Carrier, Michael A. --- "PRODUCT HOPPING: THE US APPROACH" [2019] ELECD 1285; in Figueroa, Pablo; Guerrero, Alejandro (eds), "EU Law of Competition and Trade in the Pharmaceutical Sector" (Edward Elgar Publishing, 2019) 716

Book Title: EU Law of Competition and Trade in the Pharmaceutical Sector

Editor(s): Figueroa, Pablo; Guerrero, Alejandro

Publisher: Edward Elgar Publishing

Section: Chapter 19

Section Title: PRODUCT HOPPING: THE US APPROACH

Author(s): Carrier, Michael A.

Number of pages: 17

Abstract/Description:

One of the most pressing issues in antitrust law involves “product hopping.” A brand-name pharmaceutical company switches from one version of a drug (say, capsule) to another (say, tablet). The concern with this conduct is that some of these switches offer only a relatively minor medical benefit while at the same time significantly impairing generic competition. The antitrust analysis of product hopping is complex. In the US, it implicates the intersection of antitrust law, patent law, the Hatch-Waxman Act, and state drug product selection laws. In fact, the behaviour is even more complex because it involves uniquely complicated markets characterised by buyers (insurance companies, patients) who are different from the decision-makers (physicians). This chapter introduces the relevant US laws and regulatory frameworks before exploring the five important litigated cases.


AustLII: Copyright Policy | Disclaimers | Privacy Policy | Feedback
URL: http://www.austlii.edu.au/au/journals/ELECD/2019/1285.html